MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biroccio, A.
Right arrow Articles by Zupi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biroccio, A.
Right arrow Articles by Zupi, G.

Vol. 60, Issue 1, 174-182, July 2001

C-Myc Down-Regulation Increases Susceptibility to Cisplatin through Reactive Oxygen Species-Mediated Apoptosis in M14 Human Melanoma Cells

Annamaria Biroccio, Barbara Benassi, Sarah Amodei, Chiara Gabellini, Donatella Del Bufalo, and Gabriella Zupi

Experimental Chemotherapy Laboratory, Experimental Research Center, Regina Elena Cancer Institute, Rome, Italy

Our aim in this work was to define the role of c-Myc in the susceptibility to cisplatin [cis-diamminedichloroplatinum(II) (CDDP)] in human melanoma cells. Two M14 melanoma cell clones obtained by transfection and expressing six to ten times lower c-Myc protein levels than the parental cells and the control clone were employed. Analysis of survival curves demonstrates an increase in CDDP sensitivity in c-Myc low-expressing clones if compared with the control clone and the parental line. The enhanced sensitivity is unrelated to the impairment in enzymatic DNA repair activity. Cell cycle analysis demonstrates that although the control clone is able to completely recover from the CDDP-induced S-G2/M block, this arrest is prolonged in c-Myc low-expressing clones and a fraction of cells undergoes apoptosis. Although no changes in P53, Bax, Bcl-2, and Bcl-xL/S protein levels are observed, apoptosis is associated with the formation of reactive oxygen species (ROS), activation of caspase-1, caspase-3 and cleavage of the specific caspase substrate poly-ADP-ribose polymerase. The use of the antioxidant N-acetyl cysteine and caspase inhibitors prevents CDDP-induced apoptosis in c-Myc low-expressing clones, demonstrating that ROS, caspase-1, and caspase-3 are required for apoptotic cell death. Moreover, ROS generation depends on caspase-1-like activation because the Ac-YVAD-cho inhibitor abrogates CDDP-induced ROS in the c-Myc low-expressing clones.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
B. Benassi, G. Zupi, and A. Biroccio
{gamma}-Glutamylcysteine Synthetase Mediates the c-Myc-Dependent Response to Antineoplastic Agents in Melanoma Cells
Mol. Pharmacol., October 1, 2007; 72(4): 1015 - 1023.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Parreno, J. P. Vaque, I. Casanova, P. Frade, M. V. Cespedes, M. A. Pavon, A. Molins, M. Camacho, L. Vila, J. F. Nomdedeu, et al.
Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by Myc
Mol. Cancer Ther., May 1, 2006; 5(5): 1166 - 1175.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
W. Qian, M. Nishikawa, A. Md. Haque, M. Hirose, M. Mashimo, E. Sato, and M. Inoue
Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death
Am J Physiol Cell Physiol, December 1, 2005; 289(6): C1466 - C1475.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Tonini, C. Gabellini, L. Bagella, G. D'Andrilli, V. Masciullo, G. Romano, G. Scambia, G. Zupi, and A. Giordano
pRb2/p130 Decreases Sensitivity to Apoptosis Induced by Camptothecin and Doxorubicin but not by Taxol
Clin. Cancer Res., December 1, 2004; 10(23): 8085 - 8093.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Biroccio, S. Amodei, A. Antonelli, B. Benassi, and G. Zupi
Inhibition of c-Myc Oncoprotein Limits the Growth of Human Melanoma Cells by Inducing Cellular Crisis
J. Biol. Chem., September 12, 2003; 278(37): 35693 - 35701.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Biroccio, C. Gabellini, S. Amodei, B. Benassi, D. Del Bufalo, R. Elli, A. Antonelli, M. D'Incalci, and G. Zupi
Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells
Mol. Pharmacol., March 1, 2003; 63(3): 632 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. Tentori, I. Portarena, M. Barbarino, A. Balduzzi, L. Levati, M. Vergati, A. Biroccio, B. Gold, M. L. Lombardi, and G. Graziani
Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined with Poly (ADP-Ribose) Polymerase Inhibitor
Mol. Pharmacol., January 1, 2003; 63(1): 192 - 202.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Biroccio, B. Benassi, G. Filomeni, S. Amodei, S. Marchini, G. Chiorino, G. Rotilio, G. Zupi, and M. R. Ciriolo
Glutathione Influences c-Myc-induced Apoptosis in M14 Human Melanoma Cells
J. Biol. Chem., November 8, 2002; 277(46): 43763 - 43770.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. B. Deng, H. K. Parekh, K.-C. Chow, and H. Simpkins
Increased Expression of Dihydrodiol Dehydrogenase Induces Resistance to Cisplatin in Human Ovarian Carcinoma Cells
J. Biol. Chem., April 19, 2002; 277(17): 15035 - 15043.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics